Prior art

To identify the most relevant prior art for US patent 11344552, I will examine the patent's citations. A prior art reference "anticipates" a claim under 35 U.S.C. § 102 if every element of the claimed invention is identically disclosed in a single prior art reference.

Here are some of the most relevant patent citations for US11344552B2, along with their details:

US 10993914 B2: Stabilizing camptothecin pharmaceutical compositions

• Full Citation: US 10993914 B2, "Stabilizing camptothecin pharmaceutical compositions," granted May 11, 2021.
• Publication/Filing Date: Claims priority to provisional applications filed October 16, 2015.
• Brief Description: This patent describes injectable liposome pharmaceutical products for treating cancer, specifically encapsulating camptothecin compounds (like irinotecan or topotecan) with a polyanionic trapping agent within liposomes. It also mentions that liposomal irinotecan compositions can be administered in combination with other antineoplastic agents, such as 5-fluorouracil and leucovorin for metastatic adenocarcinoma of the pancreas after gemcitabine-based therapy, or with 5-fluorouracil, leucovorin, and oxaliplatin for previously untreated pancreatic cancer.
• Potential Anticipation (35 U.S.C. § 102): This patent broadly describes a combination therapy including liposomal irinotecan, 5-FU, leucovorin, and oxaliplatin for previously untreated pancreatic cancer. This description could potentially anticipate aspects of claims 1 and 12 of US 11344552B2, particularly the general concept of the drug combination for previously untreated pancreatic cancer, as both claims involve liposomal irinotecan, oxaliplatin, 5-fluorouracil, and leucovorin for previously untreated metastatic adenocarcinoma of the pancreas. The specific dosages and administration schedules of US11344552B2 would need to be critically compared against the disclosure of US 10993914 B2 to determine if "every element" is identically shown.

US 12364691 B2: Methods for treating pancreatic cancer using combination therapies

• Full Citation: US 12364691 B2, "Methods for treating pancreatic cancer using combination therapies," granted December 26, 2023.
• Publication/Filing Date: Priority date June 13, 2012.
• Brief Description: This patent provides methods for treating pancreatic cancer by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. One embodiment specifies co-administration of liposomal irinotecan (MM-398) with 5-fluorouracil and leucovorin. It also mentions the therapy can be safely administered to patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy, with specific doses of leucovorin.
• Potential Anticipation (35 U.S.C. § 102): While this patent describes combination therapy with liposomal irinotecan, 5-FU, and leucovorin, it does not explicitly include oxaliplatin in the primary described combination for pancreatic cancer. However, if any claims in US11344552B2 are broad enough to cover combinations without oxaliplatin (which the independent claims 1 and 12 of US11344552B2 do not, as they explicitly include oxaliplatin), or if the inclusion of oxaliplatin could be considered an obvious addition given the context of other treatments, it could be relevant. Claims 1 and 12 of US11344552B2 specifically include oxaliplatin, so this patent would not directly anticipate these claims under a strict interpretation of 35 U.S.C. § 102 (requiring every element). However, it could be highly relevant for an obviousness argument under 35 U.S.C. § 103, especially if combined with other prior art teaching the use of oxaliplatin in pancreatic cancer regimens.